On October 14, 2026, the HSTECH rose 0.91% while the HSI slipped 0.13%. ILUVATAR COREX led AI concept stocks with an 8.83% gain, while BLACK SESAME fell 6.45%.
On October 14, 2026, BIDU-W (09888.HK) strengthened in the afternoon session. As of 13:47, it was quoted at HK$83.05, up 1.71%.
ASMPT (00522.HK) fell 3.28% to HKD 153.200. Huawei's new chip uses over 50 million hybrid bonds at 1.5-micron pitch, while Barclays sees DDR4 prices up 24%.
XIAOMI-W (01810.HK) rose 5.35% to HKD 26.380. A Tesla robot supplier said the design nears mass production; ASD unveiled an embodied AI innovation centre.
On 13 October 2026, HENGRUI PHARMA (01276.HK) said unit Beijing Shengdi got NMPA approval for a clinical trial of SHR-3201 injection for Alzheimer's disease.
On October 13, 2026, indices recovered with the HSI up 0.31% and the HSTECH down 0.79%. XIAOMI-W led gainers with a 2.12% gain, while PONY-W fell 8.60%.
On October 13, 2026, RoboSense (02498.HK) traded weaker. As of 13:55, it was quoted at HK$15.60, down 3.23%.
SMIC (00981.HK) fell 1.16% to HKD 55.550. Three major processor makers are raising CPU prices; Huahong Group signed deals with four domestic equipment makers.
UBTECH ROBOTICS (09880.HK) rose 0.52% to HKD 68.050. The company signed a deal with C&D to build a joint venture targeting 10,000 humanoid robot sales by 2030.
On 13 October 2026, INSILICO (03696.HK) nominated VAV1 molecular glue degrader ISM9546 as its 35th preclinical candidate since 2021, for autoimmune diseases.
On 13 October 2026, LAEKNA-B (02105.HK) said low-dose cohorts of its 24-week LAE102 study showed weight loss, lean mass gains and no serious adverse events.
On 13 October 2026, CARSGEN-B (02171.HK) said BCMA-targeted CAR T-cell product CT0596 dosed a first patient in a China Phase I trial for R/R multiple myeloma.
On 12 October 2026, SCIENTECH (02291.HK) said its MemoCarna oxide-film single-rivet PFO occluder obtained a China medical device registration certificate.
On 12 October 2026, LUZHU BIOTECH-B (02480.HK) said its RSV vaccine has been approved by the National Medical Products Administration for clinical trials.
On 12 October 2026, TH MEDICAL-B (02697.HK) said its organ perfusion system supported six gene-edited pig liver experiments for up to 144 hours, a world record.
On 12 October 2026, XPENG-W (09868.HK) traded higher. As of 14:03, the stock was quoted at HK$38.44, up 0.26%.
